In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Large Joint Replacement Market: Set For A Rebound?

Executive Summary

Beaten down by the great recession, the large joint arthroplasty market appears to be on the cusp of a turnaround, with several big players reporting encouraging Q4 and full-year 2012 results. A full recovery in this space is likely to take some time, but technology advances could help jumpstart the process, and there may be some interesting dynamics ahead in the patient-specific implant and robotic ortho device arenas.


Related Content

Stryker Enters China Race With Trauson Bid
Extremity Implants Poised For Strong Growth As Ortho Market Evolves
Could Medtronic’s Kanghui Purchase Set Course For US Entry?
Orthopedic Implants: Interest Expands In Reverse Shoulders
Medical Device Market & Industry Briefs, March 2012
At AAOS, Large Joint Makers Are Making It Personal
Total Joint Market: Slowly Recovering
Joint Arthroplasty's High-Tech Future
MAKO Surgical: Navigating Robotics in Orthopedics
Stanmore: Creating a Specialty Orthopedics Company


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts